Talia Golan's guest appearances

Talia Golan

Gastrointestinal Cancer Update

Research To Practice | Oncology Videos

Project Purple Podcast

Axel Grothey

Michael Pishvaian

Alan P Venook

E Gabriela Chiorean

Emmanuel S Antonarakis

Johanna Bendell

Ian E Krop

Tim Greten

Eileen M O’Reilly

Zev Wainberg

Andrew X

Tanios Bekaii-Saab

Philip A Philip

Yelena Y Janjigian

Peter C Enzinger

OwlTail

Pancreatic Cancer Update, Issue 1, 2020 — Our interview with Dr Golan highlights the following topics as well as cases from her practice:  Case: A man in his mid-40s with borderline-resectable adenocarcinoma of the pancreas (PAD) receives neoadjuvant FOLFIRINOX (0:00) Indications for adjuvant therapy in patients with borderline-resectable PAD (3:25) Management of borderline-resectable PAD (5:36) Selection of neoadjuvant therapy for patients with pancreatic cancer (8:06) Incidence of BRCA mutations in Israel and the United States (11:51) Case: A woman in her late 70s with node-positive, resectable PAD and multiple comorbidities receives adjuvant gemcitabine/capecitabine (14:03) Dosing and tolerability of gemcitabine/capecitabine as adjuvant therapy for elderly patients (17:36) Perspective on the role of surgical resection for older patients with pancreatic cancer (20:59) Results of the Phase III APACT trial of adjuvant gemcitabine/nab paclitaxel versus gemcitabine alone for surgically resected PAD (23:25) Choice of FOLFIRINOX versus gemcitabine/nab paclitaxel as first-line therapy for mPC (26:35) Reduction in the risk of recurrence with adjuvant therapy (28:38) Perspective on palliative and supportive care for patients with mPC (34:25) Importance of maintaining quality of life and managing depression for patients with pancreatic cancer (40:02) Role of medical marijuana in managing symptoms and treatment side effects in pancreatic cancer (42:56) Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliation and functional outcomes (46:15) Molecular profiling for patients with pancreatic cancer; spectrum of mutations in DNA damage repair genes (48:43) Design, eligibility and endpoints of the Phase III POLO trial evaluating olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with mPC and a germline BRCA mutation (52:43) POLO trial results and clinical experience with olaparib as maintenance therapy (57:02) Selection and sequencing of therapy for patients with BRCA mutations (59:53) Side effects associated with PARP inhibitors in patients with pancreatic cancer (1:04:51) Response to first-line FOLFIRINOX followed by maintenance olaparib (1:06:44) Novel approaches in the management of pancreatic cancer (1:11:40)  CME information and select publications

Pancreatic Cancer Update, Issue 1, 2020 — Our interview with Dr Golan highlights the following topics as well as cases from her practice: <ul> <li>Case: A man in his mid-40s with borderline-resectable adenocarcinoma of the pancreas (PAD) receives neoadjuvant FOLFIRINOX (0:00)</li> <li>Indications for adjuvant therapy in patients with borderline-resectable PAD (3:25)</li> <li>Management of borderline-resectable PAD (5:36)</li> <li>Selection of neoadjuvant therapy for patients with pancreatic cancer (8:06)</li> <li>Incidence of BRCA mutations in Israel and the United States (11:51)</li> <li>Case: A woman in her late 70s with node-positive, resectable PAD and multiple comorbidities receives adjuvant gemcitabine/capecitabine (14:03)</li> <li>Dosing and tolerability of gemcitabine/capecitabine as adjuvant therapy for elderly patients (17:36)</li> <li>Perspective on the role of surgical resection for older patients with pancreatic cancer (20:59)</li> <li>Results of the Phase III APACT trial of adjuvant gemcitabine/nab paclitaxel versus gemcitabine alone for surgically resected PAD (23:25)</li> <li>Choice of FOLFIRINOX versus gemcitabine/nab paclitaxel as first-line therapy for mPC (26:35)</li> <li>Reduction in the risk of recurrence with adjuvant therapy (28:38)</li> <li>Perspective on palliative and supportive care for patients with mPC (34:25)</li> <li>Importance of maintaining quality of life and managing depression for patients with pancreatic cancer (40:02)</li> <li>Role of medical marijuana in managing symptoms and treatment side effects in pancreatic cancer (42:56)</li> <li>Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliation and functional outcomes (46:15)</li> <li>Molecular profiling for patients with pancreatic cancer; spectrum of mutations in DNA damage repair genes (48:43)</li> <li>Design, eligibility and endpoints of the Phase III POLO trial evaluating olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with mPC and a germline BRCA mutation (52:43)</li> <li>POLO trial results and clinical experience with olaparib as maintenance therapy (57:02)</li> <li>Selection and sequencing of therapy for patients with BRCA mutations (59:53)</li> <li>Side effects associated with PARP inhibitors in patients with pancreatic cancer (1:04:51)</li> <li>Response to first-line FOLFIRINOX followed by maintenance olaparib (1:06:44)</li> <li>Novel approaches in the management of pancreatic cancer (1:11:40)</li> </ul> <a href="http://m.researchtopractice.com/PancreaticCancerUpdate120/Video" rel="nofollow" target="_blank">CME information and select publications</a>

Pancreatic Cancer | Talia Golan, MD

Pancreatic Cancer Update - Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Talia Golan, MD conducted by Neil Love, MD. Produced by Research To Practice.

Pancreatic Cancer Update 1 2020 | Interview with Talia Golan, MD

We spoke to Dr. Talia Golan, MD in New York City on the eve of the 2nd annual Precede Worldwide Consortium meeting. As Medical Director of the pancreatic cancer center at the Sheba Medical Center in Israel, she is working tirelessly along with other medical professionals for a cure to this terrible disease. Find out why Dr. Golan is optimistic about a future with an early detection protocol and a higher survival rate for pancreatic cancer in this week's episode.

We spoke to Dr. Talia Golan, MD in New York City on the eve of the 2nd annual Precede Worldwide Consortium meeting. As Medical Director of the pancreatic cancer center at the Sheba Medical Center in Israel, she is working tirelessly along with other medical professionals for a cure to this terrible disease. Find out why Dr. Golan is optimistic about a future with an early detection protocol and a higher survival rate for pancreatic cancer in this week's episode.

Episode 93 - Fighting For a Cure with Dr. Talia Golan, MD